Man Group’s Terns Pharmaceuticals TERN Stock Holding History

Man Group’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-284,931	Closed	-$15M	–	2600
2026 Q1	$15M	Buy	+284,931	New	+$11.7M	0.03%	641
2025 Q2	–	Sell	-38,472	Closed	-$106K	–	2383
2025 Q1	$106K	Buy	+38,472	New	+$157K	﹤0.01%	2106
2023 Q1	–	Sell	-13,763	Closed	-$132K	–	1849
2022 Q4	$140K	Buy	+13,763	New	+$91.6K	﹤0.01%	1844

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Man Group's TERN Position: Q2 2026 in Review

Man Group sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 284,931 shares — an estimated $15M sold.

Man Group first reported a position in TERN in Q4 2022 and held it in 3 quarters. The position peaked at $15M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Man Group reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Man Group sold 284,931 Terns Pharmaceuticals shares in Q2 2026, an estimated $15M.
Man Group first reported a position in Terns Pharmaceuticals in Q4 2022 and held it in 3 quarters.
Man Group's Terns Pharmaceuticals position peaked at $15M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.